Atlas Trials

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

Clinical trial NCT01442090 · COMPLETED

Trial details

NCT number
NCT01442090
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2011-10-01
Primary completion
2013-05-01
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.